"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED ACCELERATED APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) IN COMBINATION WITH PEMETREXED AND CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED NSCLC

FDA GRANTED ACCELERATED APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) IN COMBINATION WITH PEMETREXED AND CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED NSCLC

12 May 2017 9:23 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda) in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software